Venture roundup: Fusion, IsoPlexis, Tempus

On Monday, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn.) and health analytics company Tempus Labs (Chicago, Ill.) announced venture financings, raising over $100 million.

Fusion raised $21 million in the second close of a series A round, bringing the total to $46 million. New investors Adams Street Partners, Seroba Life Sciences and Varian Medical Systems joined existing investors FACIT, Genesys Capital, HealthCap, Johnson & Johnson Innovation -- JJDC Inc. and TPG Biotech. ...